Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogenic MSCs in ACLF (Liveradvance)
NCT02857010Phase 1Terminated
- Start
- Feb 2016
- Primary completion
- Feb 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in acute-on-chronic liver failure (ACLF) comparing Allogenic Mesenchymal stem cells with Placebo (2 arms). Primary endpoint: Chronic Liver Failure-Sequential Organ Failure Assessment at 28 days. Started Feb 2016; status: terminated.
02
Drugs
allogenic mesenchymal stem cells
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT02857010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02857010.